Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By

Showing results 391 - 400 of 645

7 July 2022

Chagua PrEP, Chagua Life Campaign from Kiambu County, Kenya

Chagua Life is a campaign led by LVCT Health, an implementing partner the OPTIONS Consortium. Chagua Life is a PrEP campaign for adolescent girls and young women (AGYW) in Kiambu County, Kenya.

Community/Advocacy, Demand Creation/Marketing

7 July 2022

Microbicide Trials Network-043 – B-PROTECTED Study

Microbicide Trials Network-043, or B-PROTECTED, is a Phase IIIb open-label study that evaluated the safety and acceptability of the monthly dapivirine ring and daily oral PrEP in women who are breastfeeding, a time of heightened vulnerability for acquiring HIV.

Research

External Link
7 July 2022

Use of the Dapivirine vaginal ring and effect on cervical cytology abnormalities

This study aims to determine if the dapivirine vaginal ring and the ring device alone (flexible silicone matrix polymer) was associated with the development of cervical cytology abnormalities.

Research, Service Delivery

External Link
7 July 2022

An Advocates’ Primer on Long-Acting Injectable Cabotegravir for PrEP

Results from two large-scale efficacy trials found that injectable cabotegravir (CAB-LA), given every two months, was effective as a form of pre-exposure prophylaxis (PrEP) in preventing HIV in gay men and other men who have sex with men, transgender women who have sex with men, and cisgender women. CAB-LA was developed by ViiV Healthcare and…

Community/Advocacy

External Link
7 July 2022

Results from the HPTN 083 Trial

The HIV Prevention Trials Network (HPTN) held a community webinar to discuss the preliminary results of HPTN 083, a global randomized, controlled, double-blinded study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC) (Truvada) for pre-exposure prophylaxis (PrEP) in transgender women and cisgender men who have sex…

Research

External Link
7 July 2022

HPTN 084

The HIV Prevention Trials Network (HPTN) hosted a community webinar to discuss the primary results of HPTN 084, a randomized, double-blind controlled trial designed to evaluate the efficacy and safety of long-acting injectable cabotegravir (CAB LA) to prevent the sexual acquisition of HIV in cisgender women in sub-Saharan Africa.

Research

External Link
7 July 2022

BioPIC Adaptable Product Introduction Framework

This framework is intended to inform stakeholders involved in all stages of product introduction from clinical research to rollout in low- and middle-income countries (LMICs). While the framework focuses on activities to begin in parallel to phase III clinical trials, stakeholders in early product development phases may also want to understand what to expect in…

Community/Advocacy, Demand Creation/Marketing, Financing & Costing, Research, Monitoring & Evaluation, Service Delivery, Supply Chain Management

External Link
7 July 2022

A Collaborative Approach to HIV Prevention Product Introduction

The HIV prevention product pipeline offers exciting potential to curb HIV incidence. But we know from previous products that translating trial efficacy to population impact is challenging without coordinated effort.

Community/Advocacy

External Link
7 July 2022

Knowledge, Attitudes and Practices of PrEP Providers Working with Adolescent Girls and Young Women

A review of completed, ongoing and planned studies exploring Knowledge, Attitudes and Practices of PrEP Providers Working with Adolescent Girls and Young Women

Research

Document
7 July 2022

Vaginal Ring Acceptability and Related Preferences among Women in Low- and Middle-income Countries: A systematic review and narrative synthesis

The vaginal ring (VR) is a female-initiated drug-delivery platform used for different indications, including HIV pre-exposure prophylaxis (PrEP). This article outlines a systematic review of VR acceptability, values and preferences among women in low- and middle-income countries (LMIC) to inform further investment and/or guidance on VR use for HIV prevention.

Research

External Link